Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: BD who wrote (780)	3/31/1998 8:39:00 AM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 887

This used to be an informative and civil thread. It appears that bad times seem to bring out petty bickering, blaming, and 20 20 hindsight. Many of us including myself got munched in the DEPO debacle. OK, let's get over it and move on. Given the same information I had on DEPO going into the ODAC meeting, I'd invest again in the future. I don't blame anyone on this thread or in DEPO. I accept the fact that biotech is a volatile, risky place to put my money. I'd appreciate it if the emphasis would change to an analysis of the company and its future prospects. As much as the participants in this thread have changed their view and support for DEPO, remember that neither PNU nor CHIR have wavered in their support and they know a lot more than we do. The headaches, were and are a non issue. I posted the data on them previously. DepoCyt works as well if not better than the current treatment of choice and has to be administered only one fourth as often. IMO DepoCyt will be approved. The question in my mind is not whether, but when, with what kind of label, and what will be the market size for DepoCyt. I'd appreciate hearing opinions on these issues. DepoMorphine is a potential blockbuster. It employs a drug that has been known and trusted by physicians forever. So the sales pitch is easy. The problem that I worry about is whether Physicians will reject it because they can't easily adjust the dosage. The common procedure is to administer morphine in a dose that is the best estimate of what is needed and adjust it up or down depending on the patients response. Since, DepoMorphine will be applied in a single dose for post surgical pain, there is no ability to adjust the dosage. Of course, some form of additional analgesic can be used to supplement DepoMorphine in those patients where the original dose was not sufficient. But, this is an added dimension and clinical trials would need to be run to verify the safety and efficacy of the co-administration. I'd appreciate hearing the views of others. particularly of any of the physicians who participate. I'd particularly appreciate it if we could lick our wounds and then get back on the high road of reasoned commentary on the future of DEPO and it candidate products. Sorry for the lecture. But, reading this thread has become very tiresome of late. John de C